Compare CRK & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRK | RCUS |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.2B |
| IPO Year | 1995 | 2018 |
| Metric | CRK | RCUS |
|---|---|---|
| Price | $12.98 | $15.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 15 |
| Target Price | $15.70 | ★ $40.92 |
| AVG Volume (30 Days) | ★ 2.4M | 2.0M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 288.16 | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $555,231,000.00 | $247,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $30.34 | ★ N/A |
| Revenue Growth | ★ 32.11 | N/A |
| 52 Week Low | $12.12 | $16.00 |
| 52 Week High | $28.10 | $31.74 |
| Indicator | CRK | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 39.84 | 28.86 |
| Support Level | $12.62 | N/A |
| Resistance Level | $14.18 | $24.80 |
| Average True Range (ATR) | 0.66 | 0.95 |
| MACD | -0.09 | -0.05 |
| Stochastic Oscillator | 6.16 | 2.39 |
Comstock Resources Inc is an independent natural gas producer operating in the Haynesville shale, a natural gas basin located in North Louisiana and East Texas with superior economics given its geographical proximity to the Gulf Coast natural gas markets. The Company operates in one business segment, the exploration and production of North American natural gas and oil. It is engaged in the acquisition, development, production, and exploration of oil and natural gas. The company's oil and gas operations are concentrated in Louisiana and Texas.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.